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Genetically controlled isoantigenic differences (allotypes) of 3 of the immunoglobu- 
[in  classes  of mice have recently been demonstrated  (1-7).  These  antigenic poly- 
morphisms provide useful markers in studies of protein synthesis and some aspects of 
somatic cell  genetics  (8).  Myeloma proteins produced by plasma cell  tumors have 
been particularly useful in defining the structure, subdivisions,  and genetic control of 
immunoglobulin molecules (9-11). 
The induction of plasma cell tumors in mice has been reported by several groups 
(12, 13)  using prolonged treatment of mice with mineral oil or other agents. These 
tumors have usually been produced in BALB/c mice with only the occasional  tumor 
reported in C3I-I, CBA, DBA/2, or hybrids of these strains (13). 
A new series of transplantable plasma cell tumors has recently been developed in 
hybrid mice of the cross NZB  ×  BALB/c (14).  The antigenic classification  (as de- 
fined  by Fahey et al.,  15 and  16)  of the myeloma proteins of 8 plasma cell tumors 
produced in these hybrid mice has previously been reported. It was shown that the 
8 lines comprised 4 ~'A-, 1 TGr, 1 ~'Gtb-, and 2 -/G~-myelomas. 
Some human myeloma proteins carry the isoantigens (Gin and InV)  (10, 17-19) 
of normal human immunoglobulins. These proteins carry the  Gm type of only one 
allele even from patients heterozygous at this locus (20-22).  In instances where more 
than one specificity of a Gm allele has been defined, myeloma proteins can carry these 
several specifidfies (22-24). 
We have undertaken a  detailed isoantigenic analysis of the 3 ~/Grmyelomas 
produced in (NZB  X  BALB/c)F hybrid mice, in order to see whether (a) the 
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myeloma protein carries isoantigenic specificities of one or both of the parental 
strains,  and  (b)  it carries all of the isoantigenic specificities normal  to its class 
of immunoglobulin. 
Materials and Methods 
Plasma Cdl Tumors.--The origin of the transplantable plasma cell tumors GPC-5, GPC-7, 
and  GPC-8 has been described  (14).  Each  of these plasma  cell tumors was produced  and 
passaged in (NZB X  BALB/c)IFI hybrid mice. Serawere obtained from the original hosts of 
GPC-7 and GPC-8 and from a first passage recipient of GPC-5. The serum samples were pre- 
served with 0.1% sodium azide and sent air mail from Melbourne to Paio Alto where they 
were kept at --20°C until analysis. 
Myeloma proteins from previously established lines were isolated for use as standard anti- 
gens and inhibitors. Tumors RPC-5,  (adj PC-5), MPC-1, MPC-11, MPC-31 were passaged 
in BALB/c mice; 5563 was passaged in C3H mice (15). 
Nomendakurv of Immunoglobulins.--The  nomenclature for immunoglobulin classes proposed 
(25) by the World Health Organization Committee on nomenclature of human immunoglob- 
ulins has been followed. The 5 immunoglobulin c]asses of mice defined by Fahey et al., (15, 16) 
are here called TM, 3'A, "yGI, 3zG~a, TG2b. We have changed 7S3"1 to 3'Ca etc., in order to more 
closely follow the World Health Organization Committee recommendation. 
An extension of this system for the "yG-globulins of mice is under consideration and will be 
followed when adopted. The isoantigenic(allotypic) loci for "yG~ and ~'A have previously been 
named Ig-1 and  Ig-2. In this paper  Ig-3 is the designation for the ailotypes appearing  on 
"yG~b-molecules. Specificity designation is made following the proposal of Snell et ai. (26) for 
the H-2 locus; e.g.,  for C3H "yGza-isoantigenic  specificities,  Ig-1. 1,  2,  6,  7,  8,  9,  10. 
Isolation of Myeloma Proteins--.  Zone agar gel electrophoresis of 50 #1 samples of sera from 
GPC-5,  GPC-7,  and  GPC-8 was performed in  1%  Ionagar  (Oxoid  Division, Consolidated 
Laboratories, Chicago Heights, Illinois) in veronal buffer pH 8.2 on glass plates ~t 6 to 8 v/cm, 
30 ma for 40 to 60 rain.  Serial 5 mm strips were then cut perpendicular to the direction of 
current flow and protein was extruded from these strips by centrifugation at 100,000 X  g for 
1 hr. Protein determinations on the extruded fractions revealed a  typical myeloma spike in 
the slow cathodai region.  Portions of the fractions containing these myeloma spikes were then 
iodinated or used as inhibitors. The contamination of these 3 fractions with normal gamma 
globulins is about 5% (as determined by inhibition assays for isoantigens not carried on the 
myeloma protein). 
Isoantigen~ Analysis.--Precipitation  of iodinated antigens,  inhibition of precipitation of 
iodinated antigens, and  the production of antiallotype sera, have been previously described 
(6). Briefly, the slow gamma globulins from a normal or myeloma-containing serum are puri- 
fied by ammonium sulphate precipitation, zone electrophoresis, and  Sephadex gel filtration, 
and then conjugated with 1125- by the chloramine-T method. Fifty/~1 portions of appropriate 
dilutions of a labeled antigen in 3% BSA in 0.05 ~ tris buffer, pH 7.6 are pipetted into 6 X  50 
mm tubes. To each of these is added 5/~1 of a dilution of either a purified protein antigen (the 
standard  of known protein concentration)  or a dilution of serum from normal or the plasma 
cell tumor-bearing mice. Each tube then receives 50/~1 of S-dil  (3% BSA and 10%  normal 
rabbit  serum in 0.05 ~  Tris  pH  7.6) containing a  constant  amount  of antiallotype serum 
(usually an amount previously shown to precipitate about 50% of the labeled antigen in the 
absence of inhibitor).  Control tubes contain labeled antigen and either buffer or antiserum. 
After incubation for 3 hr at 37°C, chilling to 4°C, and centrifugation at 4°C at 10,000 X  g for 
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15 min, 50/M samples of the supernatant are removed and counted in a well type crystal 
scintillation counter. The per cent of inhibition is then determined from the following  formula: 
Per cent inhibition =  (1 -- I/C) 100 where I  ffi per cent precipitation of labeled antigen 
in the tube containing labeled antigen, antiserum, and inhibitor; and C ffi per cent pre- 
cipitation of labeled antigen in the control tube containing labeled antigen and antiserum. 
Protein Conjugation to Polyaminopolystyrote (PAPS).--Conjugation of myeloma proteins 
to PAPS was performed by the diazo coupling method of Webb and LaPresle (27). The weight 
ratio of PAPS to protein was approximately 10:1, and the reaction was carried out at pH 8.2. 
Unreacted diazonium groups were blocked with glycine. Absorption of serum was performed 
by passage through a column of PAPS-protein conjugate. 
RESULTS 
Antigenic  Specificities  on  Normal  7G~-Immunoglobulins.--In  this  further 
analysis of the Ig-1 isoantigenic specificities on the class ~'G2a the same methods 
of  determination and rules  for  defining  specificities  have  been followed  as 
previously described (6). 
In listing the data used to define the presence or absence of each specificity in each of the 
type strains, the following notation is used: An Ii~-labeled preparation of gamma globulin is 
indicated with an asterisk following the symbol of the strain from which it was prepared, 
(for example, C3I-I*),  while normal sera used in inhibition  assays are listed by the strain sym- 
bols (e.g., C3H). The symbols C3H*-C57BL  anti-C3H refer to the use of a labeled C3H gamma 
globulin preparation  with a  C57BL anti-C3H  antiserum in an inhibition assay. The state- 
ment, "(C3H 8)" means C3H has specificity  8. The statement, "(C57BL -- 8)" means C57BL 
does not have specificity 8.  Myeloma proteins have occasionally been substituted  for prepa- 
rations of normal gamma globulin, when the myelomas have been found to carry all the iso- 
specifidties present on the corresponding class of gamma globulin from normal serum. Thus, 
in paragraph 5 under 3,G~-immunoglobulin RPC-5  has  been used in place of C3H gamma 
globulin. 
The Ig-1 isoantigenic specificities of "yG~ defined by the available antisera 
for the type strains are listed in Table I. 
1.  Specificity 8 was previously defined by the failure of SEA (until then undiffer- 
entiated from C3H) to completely inhibit C3H*-Cf7BL anti-C3H precipitation. The 
type strain distribution was (C3H 8; C57BL  -8; A/J 8; SEA -8) (6). 
2.  A failure of the other type strains to completely inhibit this same reaction can- 
not however be used to determine whether they have specificity 8 or not, since these 
strains lack at least one other specificity detected in this reaction. Therefore, the same 
C57BL anti-C3H antiserum was used with the iodinated gamma globulin of each of 
the other type strains to see whether that reaction could be completely inhibited by 
C3H but not by SEA. Such a  finding, could only be interpreted as the presence of 
specificity 8  in the labeled antigen. It was  found that  the precipitation of DBA* 
AK_R*, and RIII* by C57BL anti-C3H is completely inhibited by both C3H and SEA. 
CE*-C57BL anti-C3H precipitation is not completely inhibited by SEA. Therefore 
CE is the only one of these 4 type strains to have specificity 8 (DBA -8; AK_R -8; 
CE 8; RIII -8). 
3.  NZB  anfi-NZC precipitates C3H*  (NZC has  the  same  allele, Ig-1 *, as  C3H; 710  MOUSE  IMMUNOGLOBULIN ISOANTIGENS.  II 
and NZB  has the same allele  Ig-1  e as A/J). Therefore C3H has  at least one new 
specificity not previously described  (C3H 9; A/J  -9). 
4.  C57BL*-NZB anti-NZC, and CE*-NZB anti-NZC precipitations are both com- 
pletely inhibited by all type strains except AKR and A/J which do not inhibit. There- 
fore all 6 of these strains share at least 1 specificity detected by this antiserum, (C57BL 
9; DBA 9; AK.R -9; CE 9; RIII 9; SEA 9). 
5.  RPC-5*-NZB anti-NZC precipitation is completely inhibited by C3H and SEA, 
is not inhibited by AKR or A/J; and is partially inhibited by C57BL, DBA, CE, and 
RIII. Therefore in addition to detecting 9, this reaction detects a new specificity,  10, 
(C3H 10; AK.R  -10; A/J  -10; SEA 10). 
TABLE I 
Antigo~ia Spaif~#ies Conlrolted by Ig-I Alleles on "~G~-Immunoglobulins 
Allele 
Ig-i  • 
Ig-i  b 
Ig-l' 
Ig-I  d 
Ig-l* 
Ig-U 
Ig-l* 
Ig-1  h 
Type strain* 
BALB/c~J 
C57BL/10J 
DBA/2J 
AKR/J 
A/J 
cv./j 
~ii/j 
SEA/Gn 
1 
l§ 
1 
1 
1 
1 
Antigenic  specificities 
3  4 
--¶  -- 
4 
3  -- 
3  -- 
5  6 
--  6 
5 
5  6 
6 
7  8  9  10 
7  8  9  10 
7  --  9 
7  --  9 
7 
7  8 
8  9  -- 
9  -- 
7  --  9  10 
* Other strains referred to in this paper carry the following alleles: 129/J,  C3H/HeJ, 
NZC/B1,-Ig-la; LP/J,-Ig-1  b, NZB,-Ig-1  o. 
$ We have changed the Ig-t  • type strain from C3H/HeJ to BALB/cJ because of the avail- 
ability of BALB/c plasma cell tumors. 
¶ Dash indicates specificity is absent. 
§ Number indicates specificity  is present. 
Antigenic Specificities  on Normal 7G2b-Immunoglobulins.--Many  isoantisera 
have been tested for their ability to precipitate 2 l~-labeled 3,G2b-myelomas. 
Since no method for separating 3'G2b- from ~,Gu-immunoglobulins of normal 
mouse serum has so far been found, we are restricted in the analysis of 7G2b 
antigenic specificities to the use of the 3,G~s-myelomas. Hence inhibition assays 
have  been  performed with  them  in  the  manner  described  for  the  7G~-iso- 
antigens,  but using "),G2b-myeloma  proteins as labeled antigens. These assays 
are not inhibited by ~,G2,-myeloma proteins tested. MPC-11 and MPC-31 are 
BALB/c mydomas, GPC-5 is an NZB myeloma (see later). 
We  have  previously  described  isoantigens  of  ~,A-immunoglobulins  and 
termed  the  responsible  locus  Ig-2. The isoantigenic  locus  for ~,G~b-immuno- 
globulin is therefore called Ig-3. Some of these antigens have also been described 
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1.  MPC-31*-LP anti-129 precipitation is completely inhibited by C3tt, DBA, CE, 
RIII, and SEA, is partially inhibited by AKR and A/J, and is not inhibited by C57BL. 
This reaction therefore defines a minimum  of 2 specificities,  (C3tt 1, 2; C57BL -1, 
-2; DBA 1, 2; AKR 1 or 2; A/J 1,  -2; CE 1, 2; RIII 1, 2; SEA 1, 2). 
2.  GPC-5*-BALB/c anti-NZB precipitation is completely inhibited by AK_R and 
A/J and is not inhibited by any other type strains.  This reaction therefore defines 
specificity 3, (C3H  -3; C57BL  -3; DBA  -3; AK.R 3; A/J 3; CE  -3; RIII  -3; 
SEA -3)  (TableII). 
Analysis  of Isoantigenic  Specificities  on Myeloma  Proteins  GPC-5,  GPC-7, 
and  GPC-8.--Fiffy /zl  samples  of  serum  from  GPC-5,  GPC-7,  and  GPC-8 
TABLE  II 
Antigenic Specif~i~s Controlled by B~ Ig-3 Locus on 7G~-Iramunoglobulins 
strain* 
~AL~/cC,  a 
C57BL/~0J 
DBA/2J 
AKR]J 
A/it 
CE/J 
Rm/J 
SEA/Gn 
1 
1 
1 
1 
1 
1 
1 
Antigenic spec~clties 
2 
2 
or  2 
2 
2 
2 
3 
3 
* The strains listed are the type strains for Ig-1. 
tumor-bearing mice were separated by electrophoresis as described in methods. 
The  myeloma  protein  containing  fractions  were  labeled  with  r -~,  and  the 
precipitability of each of the 3 was determined with several mouse isoantisera 
(Table ]TI). These results allow some specificities to be assigned and others to 
be inferred. All specificities not listed were absent; i.e., 
GPC-S: Ig-l.5 and/or Ig-3.3 
GPC-7: Ig-1.1,2,?8;  Ig-l.6 and/or Ig-l.7; Ig-l.5 and/or Ig-3.3 
GPC-8: Ig-l.1,2, ?8; Ig-l.6 and/or Ig-l.7; Ig-l.9 and/or Ig-l.10 
Several specificlties cannot  be assigned solely on the basis of precipitation 
tests. For example, Ig-l.6 and Ig-l.7 are both detected by CE anti-129, which 
could precipitate GPC-7 and GPC-8 through  the presence of either or both of 
these speciticifies on the myeloma protein. To distinguish between these possi- 
bilities inhibition  tests were performed. 
1.  GPC.-7*-CE anti-129  precipitation  is completely inhibited  by C3H, and  only 
partially by C57BL. This indicstes that both Ig-l.6 and Ig-l.7 are on GPC-7, (GPC-7, 
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2.  GPC-7*-CE anti-129 was completely inhibited  with 0.007  gl of GPC-8 whole 
serum whereas 0.1 gl of several NZB F~ hybrid sera was needed to completely inhibit. 
This  indicates  that  GPC-8 myeloma protein  carries  specificities  Ig-l.6 and  Ig-l.7, 
as these were previously shown to be detected in this assay, (GPC-8, Ig-1.6,7). 
3.  Both  GPC-7*-C57BL anti-C3H  and  GPC-8*-C57BL anti-C3H  precipitations 
are completely inhibited by C3H but only partially inhibited by SEA. This shows that 
both myelomas carry Ig-l.8, (GPC-7 and GPC-8, Ig-l.8). 
4.  GPC-8*-NZB anti-NZC precipitation is completely inhibited by C3H but only 
partially inhibited by C57BL. This shows that GPC-8 carries both Ig-l.9 and Ig-l.10, 
(GPC-8, Ig-l.9,10). 
TABLE III 
Precipitation of Ira-Labeled Myeloma Proteins by Various Isoantisera 
Antiserum 
C57BL anti-C3H 
C3H anti-DBA/2 
C57BL anti-DBA/2 
BALB/c anfi-C57BL 
BALB/c anti-NZB 
RIII anti-129 
NZB anti-NZC 
CE anti-129 
LP anti-129~ 
Antigenic specificities 
detectable by antiserum 
ig-1  Ig-3 
1, 2, 6, 8 
3 
2, 3 
4 
5  3 
1 
9, 10 
6, 7 
--  1,  2 
Precipitation of I125-1abeled 
myeloma* 
GPC-5  GPC-7 
--  + 
--  + 
+  + 
--  + 
--  + 
GPC-8 
+ 
+ 
+ 
+ 
+ 
*  --, represents less than 2% precipitation;  +, represents greater than 50% precipitation 
(usually between 70% to 90%). 
~t Absorbed with RPC-5 myeloma conjugated to polyaminopolystyrene resin. 
The remaining  specificities  to be assigned are Ig-l.5 and  Ig-3.3, which are  both 
defined by the BALB/c anti-NZB serum. The results of inhibition assays using serial 
dilutions of the myeloma proteins are presented in Fig. 1. 
5.  GPC-5*-BALB/c anti-NZB precipitation is not completely inhibited by GPC-7. 
GPC-7*-BALB/c anfi-NZB precipitation is completely inhibited by similar amounts 
of either GPC-5 or GPC-7. This indicates that GPC-5 carries Ig-l.5 and Ig-3.3 on]y 
one of which is on GPC-7, (GPC-5, Ig-l.5, Ig-3.3). 
6.  Since GPC-7* is at least 80% precipitable by both BALB/c anfi-NZB and Rill 
anti-129 (anti-Ig-l.1), most (if not all)  GPC-7 molecules must  carry both Ig-l.1 and 
the specificity common to GPC-5 and GPC-7. Since Ig-l.1 is a ~,G,~-specificity (carried 
on the "yG~a-myelomas 5563 and RPC-5), the common specificity muzt be Ig-l.5. The 
second specificity detected by BALB/c anti-NZB present only on GPC-5, is Ig-3.3. 
The complete list of specificities present on the 3 myelomas is given in Table 
IV. Consistent with the failure of GPC-7 to completely inhibit GPC-5*-BALB/c 
anti-NZB precipitation, is the finding that absorption of the BALB/c anti-NZB N.  L.  WARNER~ L.  A.  H~RZENBERG~ AND  G.  GOLDSTEIN  713 
serum  with  GPC-7  myeloma protein  bound  to PAPS  still leaves antibodies 
which react with approximately 95 %  of GPC-5*. 
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FIGS. 1 ¢ and i b. Fig. 1 a. Inhibition of precipitation of I125-labeled  GPC-7 myeloma pro- 
tein by  GPC-5  and  GPC-7  myeloma proteins. Antiserum used  was BALB/c anti-NZB. 
Fig. 1 b. As for Fig. 1 a but using I126-1abeled  GPC-5 myeloma protein. 
TABLE IV 
Antigenic Specif~ities Present on Mydomas Originating in  (NZB X  BALB/¢) FI Hybrids 
Myeloma 
GPC-5 
GPC-7 
GPC-8 
BALB/c normal q~G2 
NZB normal ~/G2 
Ig-1 speciflcifies 
4  5  6 
5  -- 
5  6 
6 
6 
5  6 
7  8 
7  8 
7  8 
7  8 
7  8 
9  10 
9  10 
9  10 
Ig-3 specificifies 
1  2  3 
3 
1  2  -- 
1  --  3 
Analysis  of  GPC-5  with  Rabbit  Antisera.--GPC-5  has  previously  been 
typed as a  "yG~b-myeloma (14). Since it carries an Ig-1 and an  Ig-3 specificity 
further investigation of GPC-5 with rabbit anfisera was made. A  rabbit anti- 
serum  was  prepared  against  purified  MPC-11  myeloma  protein  (a  "yG,b- 
myeloma). This  antiserum was  then  absorbed once  with 5563  and  once with 714  MOUSE  YM~'UNOGLOBULIN  ISOANTIGENS.  II 
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FIo. 2. Tnhlbition of precipitation of It2S-labeled MPC-3I myeloma protein by various 
purified myelonm  proteins. Each tube contains constant amounts of labeled MPC-31 protein 
and  of rabbit  anti-MPC-11 myeloma protein serum absorbed separately with 5563 and 
RPC-5 proteins bound to PAPS. The amount of myeloma  protein used to inhibit is given. 
TABLE V 
Inhibition of Precipitation of I~-Labeled MPC-3I Mydoma by Normal 
Sera and Myeloma Protelns 
Inhibitor  Amount  Inhibition 
BALB/c whole serum 
NZB  "  " 
MPC-31 myeloma 
GPC-5  " 
GPC-5  " 
GPC-7  " 
O. 03/zl 
1.00  " 
0.02 #g 
0.02  " 
2.00  " 
3.20  " 
% 
50 
0 
50 
0 
50 
50 
Antiserum: Rabbit anti-MPC-11 myeloma absorbed with A/J normal serum conjugated 
to PAPS. 
RPC-5 protein bound to PAPS  (both ~,G~-myelomas)  to produce a  specific 
anti-NG2b-immunoglobulln antiserum. An inhibition assay was then performed 
with this  antiserum  and another 1  ~  ~/C~b-myeloma  (MPC-31),  to avoid any 
possible detection of an MPC-11  myeloma specific  antigen.  The results pre- 
sented in Fig. 2, indicate that this assay is not inhibited by any ~,G2s-myeloma 
(5563,  RPC-5,  GPC-7,  GPC-8),  nor by a  ~/A-myeloma (MPC-1).  It is coin- N.  L.  WA]~N'ER~  L.  A.  HERZENBEI~G,  AND  G.  GOLDSTEIN  715 
pletely inhibited by MPC-31, and is partially inhibited by GPC-5. This partial 
inhibition  confirms  that  GPC-5 carries qfG2b-determinants,  but also indicates 
that it lacks some determinant(s)  present on MPC-31. A/J and NZB normal 
serum were also shown to only partially inhibit this reaction. 
Another sample of the rabbit anti-MPC-11  serum was absorbed with A/J 
normal  serum  bound  to  PAPS.  This  absorbed  antiserum  still  precipitates 
labeled MPC-31 (completeness of absorption shown by its failure to precipitate 
I'~b-labeled  A/J  gamma  globulin).  This  reaction  was inhibited  by BALB/c 
normal serum but not by A/J or NZB normal sera. This indicates the presence 
of an  antigenic  determinant  on q,G~-immunogiobulins  of BALB/c type not 
present in NZB immunoglobulins.  Whereas 0.02 #g of MPC-31 protein gave a 
50 % inhibition of this assay, 0.02 #g of GPC-5 failed to inhibit at all, 100-fold 
more GPC-5 protein being needed to give the same degree of inhibition (Table 
V). A 1% contamination of this fraction with normal BALB/c ~G~b-immuno- 
globulin would account for the inhibition  observed with the GPC-5 fraction. 
This degree of contamination is expectable since this fraction was isolated from 
the serum of an (NZB X  BALB/c)F1 mouse carrying GPC-5. 
DISCUSSION 
The Ig-1 locus of mice,  previously shown to be highly polymorphic with 8 
alleles detected in some 70 inbred strains,  controls isoantigens  (ailotypes) on 
7Git-immunoglobulins.  The isoantigens determined by these alleles are com- 
prised of multiple antigenic specificities inherited as a phenogroup. Eight such 
antigenic specificities had been defined (6). This number has now been increased 
to 10, and an analysis of the Ig-3 locus,  controlling  isoantigens on the 7G~b- 
immunoglobulins has revealed at least 3 antigenic specificities. 
Before discussing  the analysis of the myeloma proteins,  some explanation 
for considering  the isoantigens on vC~ and 7G~, to be controlled by two dis- 
tinct loci Ig-1 and Ig-3 may be helpful.  The explanation is identical with that 
previously made in designating  a  distinct locus,  Ig-2,  for the allotypes (iso- 
antigens)  found on -yA-globulins (5). A gene locus is defined as the length of 
DNA which codes for a species of polypeptide chain.  In each individual mouse 
there are molecules of 5 immunoglobulin classes "},C~, 7C~, 7C~, q,A, and "yM 
which are distinguished from one another by at least the Fc fragments of their 
heavy (H) polypeptide chains  (15, 16, 28). 
These classes all differ for some of the following properties: molecular size, 
average  electrophoretic mobility  (15,  16),  physiological  (29)  and  metabolic 
behavior  (30),  and  in  antigens  (15,  16).  The  distinction  between 7C~  and 
"~'G2b was originally  made  only on  the basis of antigenic  differences.  Subse- 
quently a difference in the physiological activities of 7G~- and 7Gtb was found 
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Recently, mapping of the tryptic peptides of the Fc fragments (and of the 
entire H-chains) has shown that ~,G~- and "),G~b-class  distinctions are associated 
with polypepfide sequence differences. The Fc fragments of all ~/C~a-myeloma 
proteins tested gave tryptic peptide fingerprints identical to one another. The 
Fc fragments of all TG2b-myeloma proteins tested, also gave fingerprints identi- 
cal with each other, but, the 3'G2a- and 5'G~b-patterns  were distinctly different 
in  the position of some  18  peptides.  In addition some  12  peptides  of the  2 
types of patterns had the same position (32). This is a very welcome support 
for the immunochemical findings of cross-reactions and differences of the 3'G~a- 
and ~,G~b-FC fragments. The ~'A-fingerprints had previously been shown to be 
distinct (33). 
The above is ample reason for concluding that the molecules belonging to 
each immunoglobulin class, even within one individual mouse, have a common 
Fc polypeptide which differs from that of other classes. Thus by the definition 
of locus (above) we must assign different loci to each immunoglobulin class. 
Genetic polymorphism has so far been found only for "),G~, ~/A, and "yG~b. 
The locus designations we have assigned are Ig-1, Ig-2, and Ig-3 respectively. 
Ig-1  and Ig-2 have been shown to be closely linked genetically as have Ig-1 
and Ig-3  (5, 7).  Therefore, these loci  are clustered in a chromosome region (in 
the same sense as that used for the H-2 histocompatibility region (34) which 
may be  called  the  Ig region.  Each locus has multiple alleles  coding for the 
H-chains  (or Fc fragments) of the respective immunoglobulins. The concept 
of several linked loci for mouse immunoglobulin classes is an exact parallel of 
the postulated multiple loci controlling human "}'G-H-chain subgroups. As in 
the mouse,  individual genetic factors  (Gm  specificifies)  are  each  associated 
with a particular H-chain subgroup  (21). 
Results of analysis of 3 plasma cell tumors induced by paraffin oil injection 
into (NZB  X  BALB/c)FI hybrid mice which produce "yG~-myeloma proteins 
have been presented. NZB and BALB/c carry different alleles at both the Ig-1 
and Ig-3 loci thus providing the opportunity to analyze the role of each of the 
4  alleles  present in the hybrids in determining the allotypes of the myeloma 
proteins. The two tumors GPC-7 and GPC-8 produce ~,G~-myeloma proteins 
which will be discussed first. BALB/c and NZB  carry respectively Ig-1  ~ and 
Ig-1  ° alleles.  The antigens determined by these alleles  have several antigenic 
specificities in common, i.e.  1, 2, 6,  7, and 8, and each has at least one speci- 
ficity not present in the other; i.e., BALB/c has 9, 10; and NZB has 5 (Table 
I). Both GPC-7  and GPC-8 have all the specificities  shared by BALB/c and 
NZB, but GPC-7 has specificity 5  (associated with the Ig-1  e allele),  and does 
not have 9 and 10, while GPC-8 has the specificities  9 and 10 (associated with 
the Ig-1  ~ allele),  and does not have 5. Thus, each of these two "},Gu-myeloma 
proteins is carrying the antigenic specificifies  determined by only one  or  the 
other  of the  parental  Ig-1  alleles  present  in  the  mouse in  which  the  tumor 
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Individual myeloma proteins in man of the We and Vi class (21) also called 
72b and "r~e (35) have (with one exception) (24) been found to have only one of 
the allelically controlled antigens such as Gma, b, or f (20-22,  24),  even when 
the normal gamma globulin population is carrying several of these antigens. 
In rabbits heterozygous at the Ab locus (36),  and in mice heterozygous at the 
Ig-1 locus (37),  the two allelically controlled isoantigens have been shown to 
be located on different molecules. It has not however been conclusively elimi- 
nated  that  a  small proportion  (say 5%),  of  "heterozygous" molecules also 
exist,  and indeed such molecules can be produced in vitro by hybridization 
(38).  Rabbits heterozygous at the Ab locus have been examined by Pernis et 
al. (39) who found that the 2 aUelic types of protein were always synthesized 
in different cells.  Thus the results with GPC-7  and GPC-8  are in agreement 
with  the  general observation  that both normal and malignant cells  express 
only one H-chain or L-chain allele (at least at the time of examination). 
A  further point  should be  emphasized about  these  2  myelomas. In both 
cases,  the protein studied has been isolated from the original host of the tumor. 
It has been shown that in some mice which have been treated with prolonged 
injections of adjuvants, and in whom plasma cell tumors arise, separate tumors, 
i.e. producing different immunoglobulin polypeptide chains, can be found in 
the one host  (40).  It might be possible then that in the GPC-7  and GPC-8 
lines,  there is in fact more  than one discrete  tumor and  that the  antigenic 
specificities are  those of several myelomas. This possibility is eliminated by 
the  finding that  various  unispecific antisera  precipitate  up  to  90%  of  the 
myeloma protein (allowing a maximum of 8 %  contamination by total normal 
7Grgiobulins). These antigenic specificities are hence all on the same mole- 
cules. 
The third myeloma studied, GPC-5, may be of particular value in under- 
standing at least one aspect of the genetic control of immunoglobulins. This 
myeloma, which is also derived in a  (NZB ×  BALB/c)F1 hybrid has the anti- 
genic specificities  of only 1 parental strain (NZB). It types unambiguously as 
7G2b- myeloma with 2 rabbit antisera specific  for 7G~b. Results presented in 
this paper demonstrate that one of these rabbit antisera has antibody activity 
towards  specificities  on BALB/c 7G2b not present  on NZB  3'G2b and  adds 
further confirmation of GPC-5  being of NZB 7G2b-type.  The only antigenic 
specificities  found  on  GPC-5  are  both  defined by  the  BALB/c  anti-NZB 
serum. This myeloma carries only 1 of the 2 Ig-3 specificities  of normal NZB 
7G~b, namely Ig-3.3, but even more remarkable is the finding that it also car- 
ries a  specificity which is found on normal and myeloma NZB 7G~-immuno- 
globulins, namely Ig-l.5. On the basis of inhibition data for Ig-l.5, and with 
direct  testing by specific  antiserum to Ig-3.3,  at least  95%  of molecules of 
GPC-5 carry both specificities. 
GPC-5  is therefore the first analyzed mouse myeloma protein not carrying 
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~'G~-  or  "yG~b-molecules  previously  analyzed  do  carry  all  of  the  antigenic 
specificities  determined  by  the  respective  allele  present  in  that  individual. 
GPC-5 is also the first example of a mouse myeloma protein carrying antigenic 
specificities, and inferentially the amino acid sequences of 2 classes of immuno- 
globulins. 
To account for the occurrence of Ig-l.5 and Ig-3.3, in the same molecules of 
GPC-5, two basic alternative explanations might be proposed: 
1.  That  this  type of molecule,  despite lack of prior  detection,  is a  normal 
~,Grcomponent synthesized by a small proportion of plasma cells prior to tumor 
induction; 
2.  That  this molecular species did not exist prior  to tumor induction.  De- 
tailed  comments  on  the  specific mechanism  of  origin  of  GPC-5  should  at 
present  be limited  to a  consideration  of when  the  recombinational  or muta- 
tional event occurred. In the case of alternative  1, immediately preceding, this 
would have  been either  in  the  germ line  or in somatic  cell division  of these 
mice.  Alternative  2,  immediately  preceding,  would  require  that  this  event 
was directly related to the actual tumor induction. 
These results provide great stimulation  to continue the isoantigenic analysis 
of myeloma proteins,  in the expectation that they will throw further light on 
the  genetic control  of immunoglobulin  structure. 
SI.r~o~  ARY 
Further  analysis of the isoantigens  (allotypes) of 2 classes of normal mouse 
immunoglobulins,  "rG2a and "rG2b, has shown a minimum  of 10 specificities for 
the Ig-1 locus (controlling "rG~-antigens)  and 3 specificities for the Ig-3 locus 
(controlling "rG2b-antigens). 
Three  ~¢G2-myeloma  proteins  of plasma  cell  tumors  induced  in  (NZB  X 
BALB/c)F, mice have been analyzed for the isoantigens they carry. NZB mice 
are genotypically Ig-1  e Ig-3% while BALB/c are Ig-P Ig-3  a. Two of the mye- 
loma proteins are ~,G~,-globulins.  One of these,  GPC-7, carries all the isoanti- 
genic  specificities  of the  Ig-1  •  allele  while  the  other,  GPC-8,  carries  all  the 
isoantigenic specificities of the Ig-1 • allele. Thus only one of the parental alleles 
of the mouse in which the tumor arose is expressed in each of these myeloma 
proteins. 
The  third  myeloma protein  GPC-5,  also  carries  the  antigens  of only  one 
parental  strain  (NZB). However GPC-5,  a ~/Gz~-globulin,  carries  only one of 
the  Ig-3  specificities normally  associated  with "rG~b-globulins  of NZB.  Most 
remarkably it also carries one Ig-1 specificity normally associated with TG~- 
globulins of NZB. This is the first analyzed mouse myeloma shown (a) to ex- 
press some but not all the antigenic  specificities normally associated with an 
allele and (b) to carry antigenic specificities controlled by two distinct immuno- 
globulin  loci.  The  implications  of these  findings  are  discussed in  relation  to 
the genetic control of immunoglobulins. N. L. WA.RNER~ L. A. HERZENBERG,  AND  G. GOLDSTEIN  719 
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